OBJECTIVE: in this study profibrinolytic, antithrombotic, cytoprotective properties of defibrotide were investigated experimentally for the recovery of superior nıesenteric artery thrombosis.
STUDY DESIGN: 21 male Wistar-Albino rats were used in this study. There were three groups defined as the first. control group, ıfıe second theurapeutic defibrotide group and the third prophylactic tlıerapeutic defibrotide group. Seven rats were used in each group. in ali of the rats superior mesenteric artery thrombosis was developed. Postoperative/y in 24 hours the ischemic bowel segments with t??eir mesenteric arteries were resected and examined histopathologica/ly.
RESULTS: There was no signifıcaııt difference between the first and the second groups as far as iscfıemia was concerned (p>0.05 ). 42.8 percent of transmural necrosis was deteçted in the first group whereas none was found in the second and the third groups. There was also a significant difference between tlıe first and tlıe third groups (p<0.01 ).
CONCLUSIONS: As a conclucion defibrotide preveııts irreversible necrosis at therapeutic doses and also decreases the /eve/ at ischemia significantly when administered at prophylactic-therapeutic doses.
AMAÇ: Çalışmamızda profibrinolitik, antitrombotik ve sitoprotekti ajan olan defibrotide‘ in süperior mezenter arter trombozundaki etkisi deneysel olarak araştırıldı.
MATERYAL VE METOD: Yedişer denek halinde 3 gruba ayrılan 21 adet Wistar-Albino tipi erkek sıçan kullanıldı. Tüm deneklerde süperior mezenterik arterde trombüs oluşıurııldu. Kontrol grubundaki (/.grup), ıerapötik defibrotide grubundaki (2.grup) ve profilaktik-terapöıik defibrotide grubundaki (3.grup) tüm deneklerde, post-op 24. saatte iskemi oluşturan barsak segmeenti, mezenter arter ile birlikte rezeke edilerek histopaıolojik olarak incelendi.
BULGULAR: 1. ve 2. Grup arasında iskemi açısından anlamlı fark saptanmadı (p>0.05 ). Fakat /.grupta %42.8 oranında transmura/ nekroz tespit edilmesine karşı.n, 2. ve 3. grupta transmural nekroz saptanmadı. Ayrıca 1. ve 3. grup arasında iskemi açısıııdan anlamlı fark bulundu. (p<0.01).
SONUÇ: Defibrotide‘ nin terapötik dozda ağır nekrozu önlerken, profilakıik-terapötik verildiginde sadece ağır nekrozu önlemekle kalmayıp, iskemiyi de önemli ölçüde azalttığı sonucuna varıldı.